# Mirador Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mirador-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.miradortx.com
- Total disclosed funding: $583M
- Latest round: Series B (Sep 30, 2025)
- Investors on record: 22

## About

Founded in 2023 and based in California, US, Mirador Therapeutics, Inc. operates as a biotechnology research company focused on developing precision therapies for immune-mediated diseases. The company was co-founded by Mark C. McKenna (CEO). In February 2024, Mirador Therapeutics, Inc. raised USD 333 million in series A funding led by ARCH Venture Partners, with participation from OrbiMed Advisors, Fairmount Partners, Fidelity Management and Research Company, Point72, Farallon Capital Management, Boxer Capital, TCG Crossover Management, Invus, Logos Capital, Moore Strategic Ventures, Blue Owl Capital, Sanofi Ventures, Woodline Partners, Venrock Healthcare Capital Partners, RTW Investments, and Alexandria Venture Investments.  In September 2025, Mirador Therapeutics, Inc. raised USD 250 million in series B funding from new investors Adage Capital Management and T Rowe Price, with participation from returning investors ARCH Vnture Partners, Blue Owl, Boxer Capital, Fairmount Food Group, LLC., Farallon Capital Management, Fidelity Management and Research Company, Invus Financial Advisors, Logos Capital, Moore Strategic Ventures, OrbiMed Advisors, Point72, TCG Crossover Management, Venrock Healthcare Capital Partners, and Woodline Partners. Other unspecified investors also participated in the round.


The company utilizes a proprietary precision development engine called Mirador360, which integrates recent breakthroughs in human genetics and advanced data to harmonize patient molecular profiles, identify genetic associations, discover therapeutic targets, and develop diagnostics for precise clinical applications.

Mirador Therapeutics, Inc. plans to use the January 2026 funding to advance its clinical programs across several immune and fibrotic diseases and support the development of additional drug candidates through its research platform.

## Funding rounds

- Series B, Sep 30, 2025, $250M — ARCH Venture Partners, OrbiMed Advisors, T Rowe Price, Fairmount Food Group, LLC., Farallon Capital Management, Invus Financial Advisors, Point72 Asset Management, Moore Strategic Ventures, Fidelity Management and Research Company, Logos Capital, Venrock Healthcare Capital Partners, TCG Crossover Management, Blue Owl, Adage Capital Management, Woodline Partners, Boxer Capital
- Series A, Feb 15, 2024, $333M — ARCH Venture Partners, OrbiMed Advisors, Alexandria Venture Investments, Invus [DUP], Fairmount Partners, Sanofi Ventures, RTW Investments, Farallon Capital Management, Point72, Moore Strategic Ventures, Woodline Partners, Fidelity Management and Research Company, Logos Capital, Venrock Healthcare Capital Partners, TCG Crossover Management, Blue Owl, Boxer Capital

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Invus [DUP] — Series A
- Fairmount Partners — Series A
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series A
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series A
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series A, Series B
- Point72 (https://capitalatlas.ai/funds/point72) — Series A
- Moore Strategic Ventures (https://capitalatlas.ai/funds/moore-strategic-ventures) — Series A, Series B
- Woodline Partners — Series A, Series B
- Fidelity Management and Research Company — Series A, Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series A, Series B
- Venrock Healthcare Capital Partners (https://capitalatlas.ai/funds/venrock-healthcare-capital-partners) — Series A, Series B
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series A, Series B
- Blue Owl (https://capitalatlas.ai/funds/blue-owl) — Series A, Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series A, Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B
- Fairmount Food Group, LLC. — Series B
- Invus Financial Advisors (https://capitalatlas.ai/funds/invus-financial-advisors) — Series B
- Point72 Asset Management — Series B
- Adage Capital Management — Series B